CSL760 / CSL Behring - LARVOL DELTA

Pharmacokinetics, Safety, and Tolerability of CSL760, an Intravenous Anti-SARS-CoV-2 Hyperimmune Globulin, in Healthy Adult Subjects (clinicaltrials.gov) - P1; N=12; Terminated; Sponsor: CSL Behring; Completed ➔ Terminated; For business reasons, not a safety issue

Clinical • Trial termination • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Pharmacokinetics, Safety, and Tolerability of CSL760, an Intravenous Anti-SARS-CoV-2 Hyperimmune Globulin, in Healthy Adult Subjects (clinicaltrials.gov) - P1; N=12; Completed; Sponsor: CSL Behring; Active, not recruiting ➔ Completed; N=24 ➔ 12

Clinical • Enrollment change • Trial completion • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Pharmacokinetics, Safety, and Tolerability of CSL760, an Intravenous Anti-SARS-CoV-2 Hyperimmune Globulin, in Healthy Adult Subjects (clinicaltrials.gov) - P1; N=24; Active, not recruiting; Sponsor: CSL Behring; Recruiting ➔ Active, not recruiting

Clinical • Enrollment closed • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Pharmacokinetics, Safety, and Tolerability of CSL760, an Intravenous Anti-SARS-CoV-2 Hyperimmune Globulin, in Healthy Adult Subjects (clinicaltrials.gov) - P1; N=24; Recruiting; Sponsor: CSL Behring; Not yet recruiting ➔ Recruiting

Clinical • Enrollment open • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Pharmacokinetics, Safety, and Tolerability of CSL760, an Anti- COVID-19 Hyperimmune Intravenous Immunoglobulin, in Healthy Adult Subjects (clinicaltrials.gov) - P1; N=24; Not yet recruiting; Sponsor: CSL Behring

Clinical • New P1 trial • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases